http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2017502996-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-343 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-343 |
| filingDate | 2015-01-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2017-01-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2017502996-A |
| titleOfInvention | Administration of tasimelteon under fasting conditions |
| abstract | One embodiment of the present invention provides a method of administering tasimelteon to a human patient comprising orally administering an effective dose of tasimelteon under fasting conditions. Fasting conditions are: no food, at least 1/2 hour prior to administration, no food, at least 1 hour prior to administration, no food, at least 1.5 hours prior to administration, no food Prior to administration, at least 2 hours prior to administration, at least 2.5 hours prior to administration, or prior to administration, at least 3 hours prior to administration, and at least 3 hours prior to administration, which may include administering tasimelteon. According to such embodiments, tasimelteon may be administered, for example, at a dose of 20 mg / day. Tasimelteon may be administered, for example, when the patient is being treated for circadian rhythm disorders or sleep disorders including, for example, non-24 hour disorders. |
| priorityDate | 2014-01-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 19.